Haemonetics (HAE) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1-year price targets for Haemonetics' stock. Their HAE share price targets range from $94.00 to $115.00. On average, they predict the company's share price to reach $104.67 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for HAE or view top-rated stocks among Wall Street analysts.

Haemonetics' stock was trading at $85.51 at the beginning of 2024. Since then, HAE stock has decreased by 5.1% and is now trading at $81.16.
View the best growth stocks for 2024 here.

Haemonetics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 2,040,000 shares, a decrease of 6.4% from the March 15th total of 2,180,000 shares. Based on an average daily trading volume, of 455,600 shares, the days-to-cover ratio is currently 4.5 days. Approximately 4.1% of the company's shares are sold short.
View Haemonetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HAE earnings forecast.

Haemonetics will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, February, 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. The medical instruments supplier had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a trailing twelve-month return on equity of 22.37%. Haemonetics's revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.85 earnings per share.

ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Harbor Health Care ETF (MEDI) and AlphaMark Actively Managed Small Cap ETF (SMCP).VictoryShares US Small Cap Volatility Wtd (CSA).

Haemonetics updated its FY24 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of $3.90-4.00 for the period, compared to the consensus earnings per share estimate of $3.89. The company issued revenue guidance of ~$1.28-1.31 billion, compared to the consensus revenue estimate of $1.27 billion.

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.99%), Los Angeles Capital Management LLC (0.05%), CWM LLC (0.05%), Dynamic Advisor Solutions LLC (0.04%), Cardinal Capital Management (0.03%) and State of Michigan Retirement System (0.02%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke.
View institutional ownership trends.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.